In addition to TGF-β, a number of factors and ligands are involved in drug resistance in triple-negative breast cancers, for instance, hepatocyte growth factor (HGF) could activate Met and induce metabolic reprogramming [48]. This evidence concerns the gene TGFB1 and triple-negative breast carcinoma.